VEGFA and hepatocellular carcinoma: In the clinic, numerous tyrosine kinases2, 3, 4, 5 and monoclonal antibodies6, 7 that block VEGF or its receptors (VEGF‐R1‐3) have been shown to improve overall survival of patients with advanced hepatocellular carcinoma (HCC) in both the first‐ and second‐line setting.